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Sero-surveillanceHuman African trypanosomiasis (HAT) is a disease caused by Kinetoplastid infection. Serological tests are useful
for epidemiological surveillance. The aim of this study was to develop a multiplex serological assay for HAT to
assess the diagnostic value of selected HAT antigens for sero-epidemiological surveillance.
We cloned loci encoding eight antigens from Trypanosoma brucei gambiense, expressed the genes in bacterial
systems, and puriﬁed the resulting proteins. Antigens were subjected to Luminex multiplex assays using sera
from HAT and VL patients to assess the antigens' immunodiagnostic potential. Among T. b. gambiense antigens,
the 64-kDa and 65-kDa invariant surface glycoproteins (ISGs) and ﬂagellar calcium binding protein (FCaBP) had
high sensitivity for sera from T. b. gambiense patients, yielding AUC values of 0.871, 0.737 and 0.858 respectively
in receiver operating characteristics (ROC) analysis. The ISG64, ISG65, and FCaBP antigens were partially cross-
reactive to sera from Trypanosoma brucei rhodesiense patients. The GM6 antigen was cross-reactive to sera from
T. b. rhodesiense patients as well as to sera from VL patients. Furthermore, heterogeneous antibody responses to
each individual HAT antigen were observed. Testing for multiple HAT antigens in the same panel allowed speciﬁc
and sensitive detection. Our results demonstrate the utility of applying multiplex assays for development and
evaluation of HAT antigens for use in sero-epidemiological surveillance.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human African trypanosomiasis (HAT) causes chronic and acute
trypanosomiasis with an approximate 70 million people estimated to
be at various levels of risk of infection. At least, 57 and 12.3 million
people are at risk of T. b. gambiense and T. b. rhodesiense infection [1,2].
Moreover, over 5 million people are living in high or very high HAT
risk areas [2]. In an attempt to reduce or contain the risk, 24 out of
the 36 listed endemic countries received exclusive support fromWHO
to assess either the epidemiological status or establish control andland Ltd. This is an open access articlsurveillance activities [3]. There have been efforts to control HAT and
other NTDs [3,4] and this has led the focus into elimination of the
disease [5–7]. However, challenges have been reported [8,9]. This calls
for efﬁcient control and surveillance systems which will form the basis
for planning, implementation, monitoring and evaluation for such
intervention.
HAT is predominantly characterized by an early blood infection
stage, which is followed by a late brain infection stage. During both
stages, the parasite expresses a set of variable surface glycoproteins
(VSGs). VSGs protect the parasite from the host's immune response,
with the resulting antigenic variation leading to cyclical waves of
parasitemia as each glycoprotein is replaced by a new VSG. The variable
nature of the VSG means that HAT has properties converse to those
usually required for detection of a sero-diagnostic target [10].e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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antigens for use in the diagnosis of HAT [11–13], but direct comparison
through simultaneous detection of the diagnostic ability of these
antigens has not been previously documented.
Sero-epidemiological surveys are important in estimating disease
burden and evaluating the efﬁcacy of interventions. The use of
multiplex serological assays in such surveys will enable the detection
of multiple antigens for a given disease and the simultaneous detection
of multiple diseases. Additionally, multiplex assays can incorporate
multiple antigens encoded by a given disease, providing potential to
increase sensitivity and speciﬁcity.
We had previously described the development of amultiplex immu-
noassay system for several pathogens detection using a single limited
volume of human sample and its use in sero-epidemiological surveys
[14]. In this study, we report proof of principle for the development
and evaluation of the diagnostic ability and suitability of selected HAT
antigens in a multiplex format. To provide stable diagnosis, we selected
proteins without high sequence variability.
2. Materials and methods
2.1. Sources of human sera
A total of 139 human sera were used in this study. Of these, 119
human sera corresponded to HAT reference sera that were obtained
from the Human African Trypanosomiasis Specimen Biobank, World
Health Organization (WHO)/Organization Mondiale De La Sante/NTD-
IDM. The sera represented different stages of disease progression as
follows: T. b. gambiense, 20 negative (Cg), 20 stage-one positive (Pg1),
and 20 stage-two positive sera (Pg2); T. b. rhodesiense, 20 negative
(Cr), 3 stage-one positive (Pr1), and 36 stage-two positive sera (Pr2).
The remaining 20 human sera were derived from visceral leishmaniasis
patients and were obtained from the Rajshah Medical College in
Bangladesh. All sera were stored frozen at−80 °C.
2.2. cDNA cloning
T. b. gambiense (Kenyan strain) was kindly provided by NEKKEN
NBRP with the support of the Institute of Tropical Medicine, Nagasaki
University, which is partly supported by National Bio-Resource Project
of MEXT, Japan. The cDNAs encoding FCaBP, hypothetical 2120, hypo-
thetical 3020, ISG64, and ISG65 were ampliﬁed by PCR from genomic
DNAof the Kenyan strain. PCRprimerswere designed based on genomic
sequence for DAL972 strain. The DNA sequences of the clones were
conﬁrmed using an ABI 3730 DNA Analyzer (Applied Biosystems). The
cDNAs encoding GM6, Tbg6 and MARP were chemically synthesized
by Integrated DNA Technologies, Inc. Each cDNA was (individually)
cloned into the pET52b vector, providing expression of the proteins
with N-terminal Strep tags and C-terminal 10xHis fusion tags. Structure
of the recombinant antigens, number of tandem repeats, and accession
numbers for the reference sequences in TriTrypDB or National Centre
for Biotechnology Information (NCBI) database are shown in Table 1.Table 1
Structure of recombinant antigens expressed in pET52b vector.
Pathogen Antigen cDNA Fusion tag on N-terminus
T. b. gambiense
FCaBP PCR MASWSHPQFEKGALEVLFQGPGYQ
GM6 Synthetic MASWSHPQFEKGALEVLFQGPGYQDP
Hypothetical 2120 PCR MASWSHPQFEKGALEVLFQGPGYQDP
Hypothetical 3020 PCR MASWSHPQFEKGALEVLFQGPGYQDP
ISG64 PCR MASWSHPQFEKGALEVLFQGPGYQDP
ISG65 PCR MASWSHPQFEKGALEVLFQGPGYQDP
MARP Synthetic MASWSHPQFEKGALEVLFQGPGYQDP
Tbg6 Synthetic MASWSHPQFEKGALEVLFQGPGYQDP
* xTR indicates number of tandem repeat in antigen.2.3. Expression and puriﬁcation of the recombinant proteins
The recombinant proteins were expressed and puriﬁed as described
previously [14] except for the use of BL21 (DE3) chemically competent
cells in place of BL21Star (DE3) pLysS (Invitrogen). Among T. b.
gambiense antigens, the hypothetical 2120, ISG64, ISG65, FCaBP, GM6,
and MARP proteins were produced as part of the soluble fractions,
whereas the hypothetical 3020 and Tbg6 proteins formed inclusion
bodies. Protein concentrations of the puriﬁed antigenswere determined
using the Pierce BCA protein assay kit (Thermo Scientiﬁc).
2.4. Coupling of antigens to magnetic microspheres
Individual antigenswere dialyzed against phosphate-buffered saline
(PBS (−)) (for soluble proteins) or 0.1% N-lauroylsarcosine/PBS (−)
(for insoluble proteins) prior to coupling onto MagPlex microspheres
(Luminex). Brieﬂy, uncoupled beads were suspended in wash buffer
(PBS (−), 0.02% Tween 20) and the concentration of beads was
determined by counting under a microscope. For each antigen,
25 μg of puriﬁed protein was coupled with 1.25 × 106 microspheres.
Carboxyl groups on themicrosphereswere activated by exposure to EDC
(1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride;
Thermo Scientiﬁc Inc.) and S-NHS (N-hydroxysulfosuccinimide; Thermo
Scientiﬁc Inc.) in activation buffer (0.1MNaH2PO4, pH 6.2)with rotation
for 30 min at room temperature. The beads were then subjected to two
washes with coupling buffer (50 mM 2-(N-morpholino) ethanesulfonic
acid (MES), pH 5.0), and antigen coupling was performed by incubation
for 2 h at room temperature with gentle rotation. Blocking of the free
carboxyl group was performed using 50 mM ethanolamine pH 8.5
(Wako) for 30 min at room temperature with gentle rotation.
StabilGuard Immunoassay Stabilizer (SurModics) was used to wash
the microspheres twice and then to adjust the concentration to
1000 beads/μL. Coupled beads that showed aggregation under the
microscope were sonicated for 20 s at 10% power limit (Q500
Sonicator, QSONICA LLC.). The coupled beads were then stored at 4 °C.
Coupling of antigen to the beads was conﬁrmed using anti-His-tag
mouse monoclonal antibody (MBL, Code#D291-7), with detection
using phycoerythrin-conjugated anti-mouse IgG as the secondary
antibody (Rockland Inc., Code#710–1822) on a Bio-Plex 200 system
(Bio-Rad).
2.5. Multiplex assay
The multiplex assay was performed as described previously [14].
MagPlex beads coupled (separately) to each of eight T. b. gambiense
antigens were used for the reactions. Brieﬂy, 2.0 μL of serum was
diluted by adding in 98.0 μL of staining buffer (0.1% bovine serum
albumin, 0.05% Tween 20, 0.05% sodium azide in PBS (−), pH 7.5) in
each well of a 96-well microtiter plate. Binding reactions were
performed for 30 min at room temperature in the dark with shaking
at 750 rpm. The plate was then washed three times in 100 μl/well
staining buffer using an EL×405 microplate washer (BioTek).Antigen region xTR* Fusion tag on C-terminus Protein ID
1–230 ELALVPRGSSAHHHHHHHHHH XP_011775881
(1962 -2029) ×3 VDAAAELALVPRGSSAHHHHHHHHHH Tbg972.11.1200
1–415 VDAAAELALVPRGSSAHHHHHHHHHH XP_011774551
1–288 VDAAAELALVPRGSSAHHHHHHHHHH XP_011774088
24–365 VDAAAELALVPRGSSAHHHHHHHHHH XP_011773802
20–385 VDAAAELALVPRGSSAHHHHHHHHHH XP_011771746
(70–107) ×3 VDAAAELALVPRGSSAHHHHHHHHHH Tbg972.10.12630
(1193–1254) ×3 VDAAAELALVPRGSSAHHHHHHHHHH Tbg972.7.4640
Fig. 1. Coupling conﬁrmation by multiplex format staining of recombinant antigen-
coupled beads with anti poly-histidine tag antibody. Y axis: median ﬂuorescent intensity
of the coupled beads while the X axis represents the antigens.
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(diluted 1:250 in staining buffer) was added at 100 μL/well and the
plate was incubated for 30 min at room temperature in the dark withFig. 2. Box-plot graph for T. b. gambiense antigens. Box plots represent ﬂuorescence signals for
75th percentile boundaries; the linewithin each box indicates themedian; the red cross indicate
pathogen and disease stage: from T. b. gambiense patients, Pg1= stage1, Pg2= stage 2, and Cg
L. donovani patients, VL = visceral leishmaniasis.shaking at 750 rpm. Washing was then performed as previously
described and 125 μL of wash buffer was dispensed into each well. The
microspheres were suspended by shaking at 750 rpm for ﬁve minutes
in the dark. Fluorescence was monitored using a Bio-Plex200 system as
above.
2.6. Statistics
Receiver operating characteristics (ROC) analysis and the generation
of box plots and graphs were performed using XLSTAT software
(Addinsoft). To measure diagnostic ability of the antigens, area under
the curve (AUC) was used. Tree diagram of maximum likelihood
phylogeny was produced using CLC main workbench (CLC bio).
2.7. Ethics statement
Sampling protocol for visceral leishmaniasis patients was approved
by Ethical Committee of Rajshahi Medical College. All adult subjects
provided informed consent and a parent or guardian of any child partic-
ipant provided informed consent on their behalf. For this study, patient
signature consent was obtained.antigens. A–H: T. b. gambiense antigens. The boxes extend from the 25th percentile to the
the average; thewhiskers indicate the 10th and the 90th percentiles. Sera are indicated by
= control; from T. b. rhodesiense patients, Pr= stage 1 plus stage 2, and Cr= control; from
Table 2
ROC analysis of T. b. gambiense recombinant antigens.
Infectious species Antigen AUC* Cut off** Sensitivity
95% CI
Speciﬁcity
95% CI
Low High Low High
T. b. gambiense
ISG64 0.871 587.0 0.975 0.857 1.000 0.800 0.577 0.923
ISG65 0.737 525.5 0.575 0.422 0.715 0.850 0.629 0.954
FCaBP 0.858 567.0 0.775 0.622 0.878 0.850 0.629 0.954
T. b. rhodesiense.
ISG64 0.694 738.0 0.615 0.459 0.751 0.850 0.629 0.954
ISG65 0.494 490.0 0.487 0.339 0.638 0.700 0.478 0.855
FCaBP 0.535 559.0 0.462 0.316 0.614 0.750 0.526 0.890
*AUC; area under the curve.
**Cut off values were determined at MFI values which gave maximum sensitivity plus speciﬁcity.
Table 3
Sensitivity and speciﬁcity of T. b. gambiense antigens in multiplex assay.
Infectious
species
Positive
deﬁnition
Sample ISG64 + ISG65 + FCaBP
Proﬁle Number
#
positive
Sensitivity Speciﬁcity
T. b.
gambiense
Single Cg 20 6 0.975 0.700
Pg 40 39
Multiple
Cg 20 3
0.850 0.850
Pg 40 34
Triple
Cg 20 1
0.500 0.950
Pg 40 20
T. b.
rhodesiense
Single Cr 20 8 0.769 0.600
Pr 39 30
Multiple
Cr 20 5
0.564 0.750
Pr 39 22
Triple
Cr 20 1
0.231 0.950
Pr 39 9
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3.1. Antigen selection
A total of eight antigens from T. b. gambiense were selected for
assessment of their diagnostic utility. We selected antigens without
high sequence variability to provide stable diagnosis. Two of the
invariant surface glycoproteins (ISG64 (XP_011773802) and ISG65
(XP_011771746)), and two of the hypothetical proteins (hypotheti-
cal protein 2120 (XP_011774551) and hypothetical protein 3020
(XP_011774088)) were selected because these proteins were identi-
ﬁed by proteomics as being reactive to IgG in T. b. gambiense infection
[11]. GM6 (Tbg972.11.1200), MARP (Tbg972.10.12630), and Tbg6
(Tbg972.7.4640) are tandem-repeat-containing proteins that were
identiﬁed in animal models by screening of a cDNA library (GM6,
MARP) [13] or by bioinformatics (Tbg6) [12]. The ﬂagellar calcium-
binding protein (FCaBP, also referred to as Tb-17; XP_011775881),
is T. b. gambiense homolog of T. cruzi antigen used for diagnosis of
Chagas disease [15], which was also identiﬁed by proteomics as
being reactive to IgG in T. b. gambiense infection [11].
We cloned the genes encoding FCaBP, hypothetical 2120, hypothetical
3020, ISG64, and ISG65 by PCR ampliﬁcation from a T. b. gambiense cDNA
library; cDNAs encoding the other antigens were chemically synthesized.
DNA sequencing revealed that our ISG64 and ISG65 clones encoded
proteins withmultiple sequence changes compared to the T. b. gambiense
genomic sequence (DAL972 strain); ISG64 included 11 amino acid substi-
tutions (N236D, V241T, K242N, M244L, E245K, R293K, K294R, F298I,
T308A, H310Q, E348G); ISG65 included 15 amino acid substitutions
(N86G, G87D, P88R, G90Q, R91Y, K92N, G108E, V148Q, V150L, S151D,
E153D, T154R, N155D, S158T, G172E) as well as an extra amino acid
(i.e., one-codon) insertion after 155 N. Additionally, in our 2120 clone,
hypothetical 2120 protein was encoded with a single substitution
(P205S) compared to that encoded by the T. b. gambiense genomic
sequence (DAL972 strain). The sequences of the clones encoding
FCaBP and hypothetical 3020 were identical to those of the T. b.
gambiense genomic sequence (DAL972 strain). The structures of the
antigens used in this study are summarized in Table 1.
3.2. Coupling conﬁrmation
To determine the coupling efﬁciency, polyhistidine tags on the
antigen-coupled beads were detected in multiplex format (Fig. 1). The
resulting Median Fluorescence Intensity (MFI) values, which reﬂect
the molecular number of antigens per bead, varied from 1065 (for
ISG65) to 6364 (hypothetical protein 3020).
3.3. Reactivity of antigens
To clearly describe the reactivity of the antigens for disease-stage
determination and cross reactivity between T. b. gambiense and T. b.
rhodesiense, eight T. b. gambiense antigens were incorporated into a
multiplex assay. We assessed the diagnostic potential of the antigens
using a total of 119 HAT reference sera (from patients Cg: 20, Pg1: 20,Pg2: 20, Cr: 20, Pr1: 3, and Pr2: 36). For T. b. rhodesiense, disease stage
analysis was not performed due to the minimum number (3samples)
of stage one T. b. rhodesiense sera obtained. To access the cross reactivity
of the antigens to Leishmaniasis, which is also caused by Kinetoplastid,
20 of visceral leishmaniasis positive sera were tested. Fig. 2 provides
box-plot summaries of the resulting data.
Among the eight T. b. gambiense antigens, ISG64, ISG65, and FCaBP
were speciﬁcally reactive to sera from HAT patients; in contrast, GM6
reacted to sera from both HAT and VL patients. No positive reaction
was observed for the remaining T. b. gambiense antigens (hypothetical
2120, hypothetical 3020, MARP, and Tbg6). Notably, the ISG64, ISG65,
and FCaBP antigens were not disease stage speciﬁc because they were
not able to differentiate T. b. gambiense stages Pg1 and Pg2. Reactivity
of these antigens (ISG64, ISG65, and FCaBP) to sera from T. b. rhodesiense
patients was weaker than that observed with sera from T. b. gambiense
patients. Molecular number of coupled antigens on beads was not a
determinant of the reactivity (Figs. 1 and 2).
3.4. Sensitivity and speciﬁcity of T. b. gambiense antigens
To establish the level of reactivity of T. b. gambiense antigens, receiver
operating characteristics (ROC) analysiswas performed by grouping sera
exhibiting positive (Pg1 + Pg2 or Pr1 + Pr2) reactivity compared to
those with negative (Cg or Cr) reactivity (Table 2). None of the antigens
was disease stage speciﬁc (Fig. 2), hence analysis was done based on the
T. b. species. For T. b. gambiense patients, ISG64 showed the best area
under the curve (AUC) value at 0.871, followed by FCaBP at 0.858. AUC
values obtained for T. b. rhodesiense patients were lower than those for
T. b. gambiense patients. Cut-off values were determined at MFI values
which gave maximum sensitivity and speciﬁcity in ROC analysis
(Table 2).
In multiplex assays, positive deﬁnition by multiple antigens is
possible.We evaluated positive deﬁnition by comparing sera exhibiting
single-antigen positive, multiple-antigen positive and triple-antigen
positive reactivity against T. b. gambiense speciﬁc antigens only
(ISG64, ISG65, and FCaBP) (Table 3). For T. b. gambiense patients,
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speciﬁcity of 0.700, values that are considered high sensitivity and
low speciﬁcity because of picking up false positives (Fig. 3A). Using
multiple-antigen positive reactivity, speciﬁcity rose to 0.850 and
sensitivity to 0.850. For triple-positive reactivity, speciﬁcity rose toFig. 3.Heatmap for reactivity of each sample. A: T. b. gambiense antigens to T. b. gambiensepatien
T. b. gambiense antigens to T. b. rhodesiense patients. Cut-off valuewas calculated by comparing C
strong positive reactions (MFI value 3-fold higher than that of cut-off value) are indicated in li0.950, while sensitivity fell to a “poor” value of 0.500. The low sensitivity
observed with triple-positive reactivity reﬂected poor sensitivity of
ISG65 and FCaBP (Fig. 3A). For T. b. rhodesiense patients, the sensitivity
and speciﬁcity were lower than those for T. b. rhodesiense patients
when detection was done using T. b. gambiense-speciﬁc antigens.ts. Cut-off valuewas calculated by comparingCg vs. T. b. gambiensepatients (Pg1+Pg2). B:
r vs. T. b. rhodesiensepatients (Pr1+Pr2). Positive reactions are indicated in bright orange;
ght orange.
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To understand the meaning of the multiplex assay, the proﬁle of
reactivity for each serum was determined (Fig. 3). In T. b. gambiense
patients (Fig. 3A), double-antigen-positive sera were observed from a
combination of ISG64 + FCaBP and ISG64 + ISG65 positivity. In T. b.
rhodesiense patients (Fig. 3B), similar combinations were observed but
sensitivity by deﬁnition of multiple-positive was low because of the
low sensitivity of the individual antigens. In all sample groups, strong
positive reactions (those with MFI values at least three-fold higher
than the cut-off value) showed a variety of proﬁles. These results
suggest that HAT patients produce heterogeneous antibody against
these invariant antigens following infection.
Through inclusion of the three antigens (ISG64, ISG65 and FCaBP)
in a multiplex assay, positive deﬁnition by double antigen deﬁnition
provided an acceptable level of sensitivity and speciﬁcity for sero-
epidemiological surveillance, hence, reducing false positive and
covering heterogeneous antibody response.
4. Discussion
There is a worldwide campaign from WHO and HAT specialists to
control and eliminate HAT, but majority of the population at risk still
lives in povertywith all ages being vulnerable to the disease. Case detec-
tion andmanagement are the existing primary interventions, but suffer
from inadequate surveillance, under detection, limited access to essen-
tial medicines and drug toxicity [4,16,17]. Surveillance of HAT is key in
planning, monitoring, and policy making in prevention, control and
eradication of this disease. There are studies which have attempted to
map and express the burden of this disease [18–21], but the under
reporting and estimation has limited its true burden in the African con-
tinent. Indeed, there is need to enhance the existing surveillance tools if
control and eradication are to be achieved. The development of a sero-
epidemiological method for the determination and mapping of HAT
cases by use of advanced multiplex bead-based technology might be a
good choice for enhancement of HAT surveillance. Efﬁcacy of themulti-
plex immunoassay system is crucial and is key to the development,
hence, we utilized a literature-guided approach in antigen panel
selection. We identiﬁed candidate antigens, expressed them in E. coli,
puriﬁed, and assessed for their diagnostic potential using positive and
negative patient sera.
Variable surface glycoproteins (VSGs) cover nearly all the
membrane of trypanosomes and are the pre-dominant surface antigen
in trypanosomes making these proteins to be used as diagnostic tools
such as LitTat 1.3 and 1.5 because of their antigenicity. The variable
nature of VSGs which is intrinsically related to the surviving strategy
of African trypanosome will be cause for poor reactivity. However,
there are intracellular proteins that can also be used for diagnosis and
do not have the variable nature as the VSGs. FCaBP is a conserved intra-
cellular protein that is part of the Kinetoplastid ﬂagellum. For diagnostic
purposes, intracellular conserved proteins might be suitable to consis-
tent diagnosis, although such antigens (being intracellular) may not
be appropriate targets for vaccine development.
As demonstrated by our results, ISG64 was better than ISG65 for the
detection of IgG against T. b. gambiense. This observation contrasts that
of an earlier study, which showed that ISG65 gave the best results for
diagnosis of HAT [11]. Searches of the NCBI protein database revealed
the presence of 39 kinds of ISG64 and ISG65 (Fig. S1). In addition, our
clones for ISG64 and ISG65 had sequence variations compared to the
respective reference; identiﬁed as the best-matching sequences by
BLASTP search. Although ISG64 and ISG65 are considered “invariant”
(in contrast to the variability inherent to the VSGs), the results suggest
that ISG proteins nonetheless exhibit sequence variation among
isolates. Further studies using a higher number of individual ISGs
are required to demonstrate the relation between ISG variability
and antigenicity.In amultiplex assay, we can evaluate the diagnostic ability of several
speciﬁc antigens to a given disease simultaneously. Our data suggest
that the inclusion of several antigens for a given disease can help elim-
inate false positive results by use of double (or more)–antigen-positive
status deﬁnition; the combination of antigens also improves sensitivity
by overcoming the heterogeneity of antibody production in separate
hosts.
Identiﬁcation of new T. b. rhodesiense antigens is needed to improve
the sensitivity of ourmultiplex assay for use in T. b. rhodesiense diagnosis.
For the FCaBP, ISG64 and ISG65 antigens, further evaluation is recom-
mended using a higher number of negative and positive T. b. gambiense
sera.
Furthermore, the multiplex assay format would be a more effective
tool than conventional ELISA for the determination and selection of
useful antigens amid candidates. In the present report, we selected
three antigens from an original set of eight T. b. gambiense antigens.
Single-reaction testing of the given serum for reactivity againstmultiple
candidate antigens is expected to reduce errors while facilitating
comparison of the diagnostic ability. Such an assay is also expected to
reduce the amount of serum and time required for such tests.
5. Conclusion
We demonstrated the utility of multiplex assay in determining the
diagnostic potential of HAT antigens and combination of three T. b.
gambiense antigens (FCaBP, ISG64 and ISG65) for possible use in HAT
serological surveillance.
Nevertheless, this study needs to be further improved because of the
following limitations. There was a limited number of negative and pos-
itive sera for T. b. gambiense and T. b. rhodesiense. Only two ISG antigens
were evaluated, hence antigenicity determination between the ISGs
was limited. The lack of VL positive sera from the African population
led us to use the available Bangladesh VL sera for determination of
cross reactivity between HAT and VL.
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